The G5 Health, bringing together the leaders of the main French pharmaceutical companies (Guerbet, Ipsen, LFB, Pierre Fabre, Sanofi, Servier, Théa and bioMérieux), requested that drug price increases be financed outside of Social Security to guarantee their production in France. They recommend a dedicated sovereignty fund for 2025.
The G5 calls for applying a provision of the 2022 Social Security financing law allowing price increases on essential medicines to limit the risks of shortages. This provision favors French manufacturing by taking into account the location of production sites. It warns of the need to strengthen industrial policy in favor of products manufactured in France to restore health and industrial sovereignty.
The law allows an interministerial body to lower prices each year to contain public health spending and to grant price increases on a case-by-case basis, at the request of pharmaceutical companies, in the event of significant risk on production and distribution. marketing of a drug.
 Pascal Lemontel
|
03/10/2024 | 
